Skip to content

Study · Not a test of the peptide alone · 2007

4 results

Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R).

Handl HL, Sankaranarayanan R, Josan JS, Vagner J, Mash EA, Gillies RJ, Hruby VJ

Bioconjugate chemistry26 Jun 2007Cited by 46 (Europe PMC)

PMID17591746 (opens in a new tab)PMCIDPMC3538036 (opens in a new tab)DOI10.1021/bc0603642 (opens in a new tab)PepBankPUB-17591746
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    Bivalent MSH(7) ligands bound the human melanocortin 4 receptor with higher affinity than their monovalent counterparts.

    In plain wordsIn lab tests, linked pairs of the peptide fragment bound the MC4 receptor more tightly than the single fragment.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseBinding affinity of bivalent versus monovalent ligands
    Study

    humann: not reported in source

    Comparator
    Monovalent counterparts
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    These bivalent ligands were observed to bind with higher affinity compared to their monovalent counterparts.
    1 context sentence
    Summary · context
    This manuscript details the synthesis and evaluation of a series of bivalent ligands containing two copies of the truncated heptapeptide version of [Nle4-D-Phe7]-alpha-melanocyte stimulating hormone (NDP-alpha-MSH), referred to as MSH(7).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    Bivalent MSH(7) ligands had an optimal linker length of 25 +/- 10 A, which matched the modelled distance between adjacent receptors.

    In plain wordsIn lab tests, a linker of about 25 angstroms worked best for the linked peptide pairs.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableOptimal linker length
    Study

    humann: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Optimal linker length
    25 A
    bivalent MSH(7) ligands

    Source sentences

    Summary
    An optimal linker length of 25 +/- 10 A, inferred from these ligands, correlated well with the inter-receptor distance estimated through modeling.
    1 context sentence
    Summary · context
    This manuscript details the synthesis and evaluation of a series of bivalent ligands containing two copies of the truncated heptapeptide version of [Nle4-D-Phe7]-alpha-melanocyte stimulating hormone (NDP-alpha-MSH), referred to as MSH(7).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    Maximal binding affinity did not differ between bivalent ligands with Pro-Gly repeats and those with PEGO inserts.

    In plain wordsIn lab tests, the two linker types gave the same top binding strength.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeMaximal binding affinity, Pro-Gly versus PEGO linkers
    Study

    humann: not reported in source

    Comparator
    Ligands with PEGO inserts
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Although there was no difference in maximal binding affinities between the ligands constructed with the Pro-Gly repeats versus those constructed with the PEGO inserts, the PEGO-containing ligands bound with high affinities over a greater range of linker lengths.
    1 context sentence
    Summary · context
    This manuscript details the synthesis and evaluation of a series of bivalent ligands containing two copies of the truncated heptapeptide version of [Nle4-D-Phe7]-alpha-melanocyte stimulating hormone (NDP-alpha-MSH), referred to as MSH(7).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  4. 04LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    PEGO-containing bivalent ligands bound with high affinity over a greater range of linker lengths than ligands with Pro-Gly repeats.

    In plain wordsIn lab tests, linked pairs with PEGO inserts bound well over a wider range of linker lengths.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseRange of linker lengths with high affinity binding
    Study

    humann: not reported in source

    Comparator
    Ligands with Pro-Gly repeats
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Although there was no difference in maximal binding affinities between the ligands constructed with the Pro-Gly repeats versus those constructed with the PEGO inserts, the PEGO-containing ligands bound with high affinities over a greater range of linker lengths.
    1 context sentence
    Summary · context
    This manuscript details the synthesis and evaluation of a series of bivalent ligands containing two copies of the truncated heptapeptide version of [Nle4-D-Phe7]-alpha-melanocyte stimulating hormone (NDP-alpha-MSH), referred to as MSH(7).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.